SummaryRMgm-159
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 19016774 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter (PubMed: PMID: 16242190). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | M. Steinbuechel; K. Matuschewski |
Name Group/Department | Department of Parasitology |
Name Institute | Heidelberg University School of Medicine |
City | Heidelberg |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-159 |
Principal name | S6-; TREP- (A1) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of midgut sporozoites are formed. Strong reduction in numbers of salivary gland sporozoites. The deficiency to enter mosquito salivary glands was accompanied by substantial accumulation of viable sporozoites in the mosquito haemocoel. Strong reduction of gliding motility of oocyst-derived/hemolymph sporozoites. Invasion of hepatoma cells in vitro of purified oocyst-derived/hemolymph sporozoites was strongly reduced. Infection of mice/rats by mosquito bite or by inoculation of purified oocyst-derived/hemolymph sporozoites resulted in blood stage infections. |
Liver stage | Invasion of hepatoma cells in vitro of purified oocyst-derived/hemolymph sporozoites was strongly reduced. Infection of mice/rats by mosquito bite or by inoculation of purified oocyst-derived/hemolymph sporozoites resulted in blood stage infections, comparable to wild type |
Additional remarks phenotype | Mutant/mutation Protein (function) See also GenBank accession number FJ160771 (S6) and FJ167344 (TREP) for the correct sequence of the gene encoding S6/TREP. Adhesion of sporozoites of this mutant has been analysed in another study (Hegge et al., 2010, FASEB J; PMID: 20159960). Mutant sporozoites showed significant weaker adhesion on glass slides as compared to wild type parasites. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1306500 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1442600 | ||||||||||||||||||||||||
Gene product | TRAP-like protein | sporozoite-specific transmembrane protein S6 | ||||||||||||||||||||||||
Gene product: Alternative name | TREP; TRAP-related protein, S6; sporozoite specific gene 6; UOS3 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI/SacII | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | Two targeting fragments were selected from the non-coding regions of S6. A 1045 bp fragment of the 5' UTR and a 807 bp fragment of the 3' UTR | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |